At lower end of guidance $20m revenue at say 20% net profit margin = $4m EBIT, and around $2.8m NPAT.
404m shares so 0.69 cents per share, puts this at a P/E of 60.
At higher end of guidance $50m revenue, $10m EBIT, $7m NPAT, 1.7c/share, P/E of 25.
Float price would seem fair value, and current price overbought, unless there's significant growth potential for beyond 12 months.
I would say the flipside is likely and covid-19 may not be a huge problem beyond the pandemic phase and they are back to $5-8m revenue from HIV test kits in 2-3 years time.
- Forums
- ASX - By Stock
- 50% margin ? The product
At lower end of guidance $20m revenue at say 20% net profit...
-
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AT1 (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
0.001(2.50%) |
Mkt cap ! $13.10M |
Open | High | Low | Value | Volume |
2.0¢ | 2.1¢ | 2.0¢ | $121 | 6.039K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 1749919 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 32000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 1749919 | 0.020 |
3 | 695000 | 0.019 |
4 | 462414 | 0.018 |
3 | 65000 | 0.017 |
2 | 37500 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 32000 | 1 |
0.022 | 53184 | 2 |
0.023 | 200000 | 1 |
0.024 | 113559 | 2 |
0.025 | 9000 | 1 |
Last trade - 12.49pm 06/09/2024 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |